Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in the Netherlands
On March 18, 2025, Telix announced that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), received marketing authorization from the Medicines Evaluation Board (MEB) in the Netherlands. This approval allows healthcare providers in the country to use Illuccix® for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer. The product is now available under a broad clinical label, enabling its use for PSMA-PET imaging with a clinically validated gallium-based ra...